Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Atsunaga Kato"'
Publikováno v:
Regenerative Therapy, Vol 27, Iss , Pp 230-233 (2024)
Introduction: Endotoxin is a typical pyrogen derived from the outer membrane of Gram-negative bacteria. In fabricating cell-based medicinal products, it is necessary to control endotoxin in the process and the products. In the quality control tests o
Externí odkaz:
https://doaj.org/article/622e68cd732d42868a3973a33c13c086
Autor:
Noboru Hirashima, Yasuhito Tanaka, Hajime Kondo, Kenji Sakakibara, Hideaki Kato, Tomoyuki Sakamoto, Ken-ichi Ohba, Fuminaka Sugauchi, Atsunaga Kato, Masashi Mizokami, Haruhiko Nukaya, Takanobu Kato, Ryuzo Ueda, Tomoyoshi Ohno, Seijiro Matsunaga, Etsuro Orito
Publikováno v:
Hepatology Research. 29:9-12
Recently, lactoferrin has been reported to have anti-HCV effects. The aim of this study was to investigate the effect of combination therapy using consensus interferon (CIFN) and lactoferrin in patients with chronic hepatitis C. Twenty-one patients w
Autor:
Kenji Sakakibara, Atsunaga Kato, Hajime Kondo, Takanobu Kato, Izumi Hasegawa, Fuminaka Sugauchi, Tomoyuki Sakamoto, Yutaka Kondo, Ryuzo Ueda, Masashi Mizokami, Haruhiko Nukaya, Ken-ichi Ohba, Noboru Hirashima, Yasuto Tanaka, Seijiro Matsunaga, Noboru Shinkai, Etsuro Orito, Tomoyoshi Ohno
Publikováno v:
Kanzo. 45:211-215
症例は53歳, 男性. 1992年3月, C型慢性肝炎に対しインターフェロンα 2aを投与するもC型肝炎ウイルス (HCV) は消失せず, 強力ネオミノファーゲンC投与を続けていた. 2001年2月6日, S6に肝細胞癌
Autor:
Kazuharu Mega, Atsunaga Kato, Masashi Ueyama, Katsuyuki Yamashita, Takuya Inoue, Nobuyuki Harunari, Jun Oda
Publikováno v:
Nihon Kyukyu Igakukai Zasshi. 15:107-112
Autor:
Noboru SHINKAI, Noboru HIRASHIMA, Kenji SAKAKIBARA, Makoto OYAMA, Kiyoaki ITO, Atsunaga KATO, Haruhiko NUKAYA, Hiromu KONDO, Etsuro ORITO, Masashi MIZOKAMI
Publikováno v:
Kanzo. 43:203-206
Autor:
Motokazu Mukaide, Kanji Sugihara, Makoto Nakamura, Hideki Hiramatsu, Masakazu Nitta, Ryuzo Ueda, Atsunaga Kato, Masashi Mizokami, Takanobu Kato
Publikováno v:
Hepatology Research. 9:164-171
A novel virus, GB virus C/hepatitis G virus (GBV-C/HGV), is believed to be a member of the Flaviviridae and to be closely related to the hepatitis C virus (HCV), according to phylogenetical analysis. However, hepatitis-associated aplastic anemia (HA-
Autor:
Haruhiko, Nukaya, Shinichi, Kajino, Hiroshi, Tokuda, Yoshito, Tanaka, Izumi, Hasegawa, Atsunaga, Kato, Takashi, Joh
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 37(9)
We report an investigation of the therapeutic efficacy and safety of combination chemotherapy with docetaxel (DOC) and doxifluridine (5'-DFUR) administered as second-line or third-line chemotherapy in 23 cases of unresectable and/or advanced gastric
Autor:
Tomoyoshi, Ohno, Hiroki, Koguchi, Aki, Miura, Yoshito, Tanaka, Masayuki, Endo, Seijiro, Matsunaga, Izumi, Hasegawa, Atsunaga, Kato, Yasushi, Tokuda, Kenji, Sakakibara
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 36(6)
The patient was a 53-year-old male who was admitted on an emergency basis with obstructive jaundice. He was diagnosed as having advanced ampullary carcinoma(T4 N0 H1, Stage IV b). To reduce the degree of obstructive jaundice, a self-expandable metall
Autor:
Izumi Hasegawa, Haruhiko Nukaya, Yoshito Tanaka, Kenji Sakakibara, Etsuro Orito, Masashi Mizokami, Seijiro Matunaga, Fuminaka Sugauchi, Tomoyoshi Ohno, Yasuhito Tanaka, Masayuki Endo, Atsunaga Kato
Publikováno v:
Hepatology research : the official journal of the Japan Society of Hepatology. 38(7)
Aim In chronic hepatitis C virus (HCV) infection, it is thought that both chronic persistent inflammation and oxidative stress contribute to the development of hepatocellular carcinoma (HCC), and it has been reported that long-term oral supplementati
Autor:
Haruhiko, Nukaya, Noboru, Hirashima, Yoshito, Tanaka, Masayuki, Endo, Seijiro, Matsunaga, Izumi, Hasegawa, Atsunaga, Kato, Kenji, Sakakibara, Tomoyuki, Sakamoto, Hiromu, Kondo
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 32(10)
We report an investigation of the therapeutic efficacy and safety of TS-1 single-agent therapy administered as first-line therapy in 23 cases of unresectable advanced gastric cancer treated at our institution. TS-1 was administered at 80 mg-120 mg (d